AZN,GSK -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters12 hours ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organisation and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • Reuters12 hours ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organization and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • Why This Biotech Stock Could Outperform Expectations In Lung Cancer
    Investor's Business Daily15 hours ago

    Why This Biotech Stock Could Outperform Expectations In Lung Cancer

    AstraZeneca could bring in $3.8 billion in peak sales of immuno-oncology drug Imfinzi, an analyst said Thursday.

  • J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
    Zacks22 hours ago

    J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

    Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

  • Benzinga2 days ago

    Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says

    Shares of the clinical-stage biotech company  Pieris Pharmaceuticals Inc (NASDAQ: PIRS ) are poised to outperform over the coming 12 to 18 months, according to William Blair.  The Analyst William Blair ...

  • SmarterAnalyst2 days ago

    Here’s Why Neurometrix Inc Rose as Much as 60% Today

    Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.

  • Reuters2 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.

  • Reuters2 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region.

  • Nektar Boasts Strong Pipeline, Competition Remains a Woe
    Zacks2 days ago

    Nektar Boasts Strong Pipeline, Competition Remains a Woe

    Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

  • Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018
    Market Realist2 days ago

    Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018

    How Is Amgen Positioned for 2018?

  • MarketWatch2 days ago

    NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell

    Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...

  • Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
    Bloomberg2 days ago

    Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa

    GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...

  • Dow's Merck Does An About-Face, Releases Cancer Trial Results
    Investor's Business Daily3 days ago

    Dow's Merck Does An About-Face, Releases Cancer Trial Results

    Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.

  • What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?
    Simply Wall St.3 days ago

    What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as GlaxoSmithKline plc (LSE:GSK) a safer option. Market participants who are conscious of risk tend toRead More...

  • AstraZeneca's Lynparza Label Now Includes Breast Cancer
    Zacks4 days ago

    AstraZeneca's Lynparza Label Now Includes Breast Cancer

    AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

  • Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
    Zacks4 days ago

    Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

    Global markets endured a volatile week, guided by opposing factors.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist4 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
    Zacks4 days ago

    Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

    Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist7 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist7 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • US OKs 1st drug aimed at women with inherited breast cancer
    Associated Press7 days ago

    US OKs 1st drug aimed at women with inherited breast cancer

    U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist7 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Reuters7 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • Reuters7 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene. The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
    Zacks7 days ago

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.